Coronary Artery Disease Therapeutics Market 2021 Analysis, Growth, Size, Shares, Drivers, Advancements, Challenges, Sophisticated Demand & Key Performers 2027
SEATTLE, April 01, 2021, (PHARMIWEB) — Coronary Artery Disease (CAD) is the narrowing or blockage of the coronary arteries that is caused by atherosclerosis. In layman’s term, atherosclerosis is the buildup of cholesterol and fatty deposits of on the inner walls of arteries. Increasing deposition of plague eventually narrows the coronary arteries thereby decreasing the blood flow to the heart. This results in shortness of breath and chest pain, eventually leading to heart attack after complete blockage. Coronary artery disease is mainly caused by smoking, high blood pressure, high cholesterol, diabetes or insulin resistance, sedentary lifestyle, and hypertension. Moreover, obesity, physical inactivity, high stress, and unhealthy diet are responsible for this disease. Coronary artery disease can be prevented by maintaining healthy diet, consumption of low fat and low salt fruits and vegetables, physical activity, and management of stress. Treatment of coronary artery disease includes cholesterol modifying medications, ACE inhibitors, Aspirin, beta blockers, Calcium channel blockers, and Ranolazine. Surgeries conducted to treat coronary artery disease include Nitroglycerin, Angioplasty, and coronary artery bypass surgery.
To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/1799
Market Dynamics- Drivers
Robust pipeline of drugs available worldwide is expected to drive growth of the global coronary artery disease therapeutics market over the forecast period (2018-2026). For instance, hydroxychloroquine sulfate tablets sponsored by first affiliated hospital of Xi’an Jiaotong university, China is in the fourth phase of clinical trials, this drug suppresses symptoms of coronary artery disease. Atorvastatin sponsored by university health network, Toronto has completed phase two clinical trials in 2014, this drug reduces the risk of heart attack and myocardial infraction. PADMA 28 sponsored by University hospital Inselsiptal, Berne has completed phase 2 clinical trials in 2013, this drug has beneficial effect on arterial system, the autonomic nervous system and blood inflammatory markers in patients with coronary artery disease.
Furthermore, constant drug approvals for coronary artery disease from regulatory agencies is expected to propel the global coronary artery disease therapeutics market growth in the near future. For instance, in 2016, the U.S. Food and Drug Administration (FDA) approved Yosprala (Aspirin and Omeprazole) by Aralez Pharmaceuticals, a Canada-based company, this drug is used to prevent cardiovascular diseases. In 2015, FDA approved Repatha by Amgen Inc. This drug is used to treat high cholesterol. In 2015, FDA approved Prestalia by Symplmed Pharmaceuticals LLC, this drug is used to treat hypertension for people suffering with heart disorders. Later in 2017, Prestalia was acquired by Marina Biotech Inc.
Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://bit.ly/3sL8iOr
Market Dynamics- Restraints
High cost associated with new drugs is expected to restrain growth of the global coronary artery disease therapeutics market growth in the near future. For instance, Entresto was launched by Novartis, a U.S.-based company, indicated for preventing heart failures. It is priced at US$ 492 for 60 tablets, which is not affordable to low and middle income population.
Among regions, North America is expected to hold dominant position in global coronary artery disease therapeutics market during the forecast period. This is owing to high prevalence of coronary artery disease in the region. According to a survey conducted by Centers for disease control and prevention (CDC), in 2015, coronary heart disease kills over 370,000 people annually in the U.S. out of which more than 92% had chest pain as a major symptom. According to a study conducted by American College of Cardiology, in 2017, more than 790,000 people experience heart attack annually in the U.S. out of this around 47% people were reported to have hypertension and around 34% were reported to have high blood pressure. Furthermore, Asia Pacific coronary artery disease therapeutics market is expected to witness significant growth rate, owing to constant regulatory approvals of generic drugs. For instance, in 2017, Lupin, India-based Company received the U.S. FDA approval to launch generic version of Nadolol Tablets, indicated for the treatment of hypertension and angina pectoris.
Key players operating in the global coronary artery disease therapeutics market include Astra Zeneca, Gilead, Novartis, Pfizer, Bayer, Merck & Co, Glaxo Smith Kline, and Mylan N.V.
*The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.
Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1799
Global Coronary Artery Disease Therapeutics Market Taxonomy:-
The global coronary artery disease therapeutics market is segmented based on drug type, distribution channel and region.
By Drug Type:-
- Beta Blockers
- Calcium Channel Blockers
- ACE Inhibitors
By Distribution Channel:-
- Online Pharmacies
- Retail Pharmacies
- North America
- Latin America
- Asia Pacific
- Middle East
Table of Content
Global Coronary Artery Disease Therapeutics Market Research Report
Section 1: Global Coronary Artery Disease Therapeutics Industry Overview
Section 2: Global Economic Impact on Coronary Artery Disease Therapeutics Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Coronary Artery Disease Therapeutics Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Coronary Artery Disease Therapeutics Market Forecast
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire